UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Deutsches Ärzteblatt international, 05/2019, Volume 116, Issue 20, p. 363
Journal Article
Anticancer research, ISSN 0250-7005, 03/2018, Volume 38, Issue 3, pp. 1335 - 1341
Vemurafenib | V600E mutant BRAF | Melanoma | Dabrafenib | BRAF inhibitor | BRAF | Radiotherapy | Life Sciences & Biomedicine | Oncology | Science & Technology | Biotechnology | Ionizing radiation | Inhibitors | Radiosensitization | Cell survival | Cell death | Test procedures | Tumor cell lines | Survival | Necrosis | Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 04/2018, Volume 71, Issue 16, pp. 1755 - 1764
pembrolizumab | cardio-oncology | nivolumab | myocarditis | ipilimumab | checkpoint inhibitor | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Glucocorticoids - therapeutic use | Myocarditis - chemically induced | Methylprednisolone - therapeutic use | Myocarditis - complications | Humans | Middle Aged | Myocarditis - drug therapy | Male | Myocarditis - blood | Case-Control Studies | Neoplasms - drug therapy | Antineoplastic Agents, Immunological - adverse effects | Troponin T - blood | Female | Registries | Aged | Heart | Statistical analysis | Toxicity | Diabetes mellitus | Melanoma | Medical records | Cancer therapies | Patients | Regulatory approval | Troponin T | Confidence intervals | Myocarditis | Side effects | Troponin | Inhibitors | Immune checkpoint | Calcium-binding protein | Blood pressure | Heart diseases | Steroid hormones | Steroids
Journal Article
Anticancer research, ISSN 0250-7005, 09/2020, Volume 40, Issue 9, pp. 4937 - 4946
Life Sciences & Biomedicine | Oncology | Science & Technology | Phosphorylation | Cell survival | Small cell lung carcinoma | Lung cancer | Radiation | Non-small cell lung carcinoma | Radiation therapy | Kinases | Lymphoma | Synergistic effects | Radiosensitization | Inhibitors | Cell death | Cell cycle | Irradiation | Combined treatment | Protein-tyrosine kinase | Index Medicus
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 2017, Volume 75, pp. 24 - 32
Hematology, Oncology and Palliative Medicine | Autoimmunity | Metastatic melanoma | Pembrolizumab | Immune-related adverse events | Nivolumab | Ipilimumab | PD-1 inhibitor | Life Sciences & Biomedicine | Oncology | Science & Technology | Melanoma - complications | Recurrence | Skin Neoplasms - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Neoplasm Metastasis | Antineoplastic Agents - adverse effects | Autoimmunity - immunology | Adult | Female | Retrospective Studies | Autoimmune Diseases - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Skin Neoplasms - immunology | Autoimmune Diseases - complications | Skin Neoplasms - complications | Melanoma - immunology | Melanoma - drug therapy | Aged | Autoimmune Diseases - chemically induced | Autoimmunity - drug effects | Medical colleges | Care and treatment | Melanoma | Biochemistry | Skin | Metastasis | Skin cancer | Apoptosis | Medical research | Therapy | PD-1 protein | Disorders | Clinical trials | Patients | Immunosuppressive agents | Metastases | Inhibitors | Cell death | Colitis | Autoimmune diseases | Tumors | Index Medicus
Journal Article
Journal of cancer research and clinical oncology, ISSN 0171-5216, 10/2019, Volume 145, Issue 10, pp. 2625 - 2631
C-reactive protein | Medicine & Public Health | Hematology | Adverse events | Melanoma | Oncology | Cancer Research | Internal Medicine | Immune checkpoint inhibitors | Life Sciences & Biomedicine | Science & Technology | Proteins | Complications and side effects | Medical research | Analysis | Communicable diseases | Medicine, Experimental | Development and progression | Index Medicus
Journal Article
Immunotherapy, ISSN 1750-743X, 01/2017, Volume 9, Issue 2, pp. 115 - 121
eosinophils | melanoma | biomarker | prognosis | immunotherapy | blood eosinophilia | Life Sciences & Biomedicine | Immunology | Science & Technology | Immunotherapy - methods | Melanoma - diagnosis | Prognosis | Cell Count | Humans | Middle Aged | Male | Biomarkers, Tumor | Young Adult | Neoplasm Metastasis | Animals | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Eosinophils - pathology | Melanoma - therapy | Melanoma - mortality | Antigens | Immunization | Statistical analysis | Cell survival | Cytokines | Leukocytes (eosinophilic) | Melanoma | Cytotoxicity | Vaccines | Metastasis | Cancer therapies | Eosinophilia | Metastases | Skin cancer | Pembrolizumab | Immune checkpoint | Lymphocytes | Immunotherapy | Medical prognosis | Peripheral blood | Biomarkers | Hypoxia | Hodgkin's disease | Tumors
Journal Article
International journal of cancer, ISSN 0020-7136, 03/2019, Volume 144, Issue 5, pp. 1147 - 1150
melanoma | immunosenescence | immune checkpoint inhibitors | biomarker | Life Sciences & Biomedicine | Oncology | Science & Technology | Tumor Necrosis Factor Receptor Superfamily, Member 7 - immunology | Flow Cytometry - methods | CD57 Antigens - immunology | Humans | Middle Aged | Male | CD28 Antigens - immunology | Biomarkers, Tumor | Lymphocytes - immunology | Melanoma - immunology | Aged, 80 and over | Female | Immunosenescence - immunology | Aged | Hepatitis A Virus Cellular Receptor 2 - immunology | CD57 antigen | CD27 antigen | Flow cytometry | Therapy | Phenotypes | Senescence | Leukemia | Lung cancer | Melanoma | Lymphocytes T | CD28 antigen | Patients | Metastases | Inhibitors | Immune checkpoint | Lymphocytes | Correlation analysis | Phenotyping | Peripheral blood | Biomarkers | Immunosenescence | Surface markers | Immune system | Index Medicus
Journal Article
Cancers, ISSN 2072-6694, 01/2021, Volume 13, Issue 2, p. 221
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 2016, Volume 65, pp. 182 - 184
Hematology, Oncology and Palliative Medicine | Pembrolizumab | Anti-PD-1 | Combined immunotherapy | Ipilimumab | Melanoma | Life Sciences & Biomedicine | Oncology | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Immunotherapy - methods | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Antineoplastic Agents - therapeutic use | Drug Therapy, Combination - adverse effects | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Melanoma - drug therapy | Aged, 80 and over | Female | Aged | Complications and side effects | Metastasis | Analysis | Immunotherapy | Index Medicus
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 01/2019, Volume 106, pp. 12 - 23
Neuromuscular side effects | Myositis | Immune checkpoint inhibitors | Tocilizumab | Life Sciences & Biomedicine | Oncology | Science & Technology | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Myositis - chemically induced | Myositis - immunology | Myositis - therapy | Young Adult | Neoplasm Metastasis | Time Factors | Aged, 80 and over | Adult | Female | Registries | Retrospective Studies | Neuromuscular Diseases - diagnosis | Databases, Factual | Neuromuscular Diseases - immunology | Skin Neoplasms - pathology | Molecular Targeted Therapy - adverse effects | Neuromuscular Diseases - chemically induced | Risk Assessment | Skin Neoplasms - immunology | Risk Factors | Myositis - diagnosis | Switzerland | Neuromuscular Diseases - therapy | Antineoplastic Agents, Immunological - adverse effects | Aged | Germany | Complications and side effects | Creatine | Skin cancer | Therapy | PD-1 protein | Creatine kinase | Clinical trials | Antibodies | Metastases | Proteins | Pembrolizumab | Myasthenia gravis | Immunotherapy | Heart diseases | Movement disorders | Neuromuscular diseases | Complications | Patients | Myocarditis | Side effects | Inhibitors | Immune checkpoint | Cell death | Polymyalgia rheumatica | Neuromuscular junctions | Muscle function | Skin | Myasthenia | Steroid hormones | Steroids | Cancer | Index Medicus
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 2017, Volume 75, pp. 47 - 55
Hematology, Oncology and Palliative Medicine | Pembrolizumab | Anti-PD-1 | Nivolumab | Ipilimumab | Melanoma | Disease progression | Treatment failure | Efficacy | Ipilimumab and nivolumab | Life Sciences & Biomedicine | Oncology | Science & Technology | Skin Neoplasms - drug therapy | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Treatment Outcome | Disease Progression | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Skin Neoplasms - mortality | Melanoma - drug therapy | Aged, 80 and over | Adult | Female | Aged | Retrospective Studies | Melanoma - mortality | Antimitotic agents | Medical colleges | Care and treatment | Cell death | Development and progression | Skin | Antineoplastic agents | Cancer | Therapy | PD-1 protein | Medical prognosis | Disease control | Patients | Survival | Apoptosis | Tumors | Index Medicus
Journal Article
International journal of molecular sciences, ISSN 1661-6596, 12/2020, Volume 21, Issue 23, p. 9321
TOR protein | Flow cytometry | Biotechnology | Cell culture | Homologous recombination | DNA damage | Lung cancer | Clinical trials | Cytotoxicity | Homology | Metastasis | Kinases | DNA repair | Cancer therapies | Necrosis | Ewings sarcoma | Metastases | Skin cancer | Proteins | Cell cycle | Fibroblasts | Drug dosages | Deoxyribonucleic acid--DNA | Cell survival | Melanoma | I.R. radiation | Rapamycin | Radiation therapy | Gene expression | Double-strand break repair | Patients | Lymphoma | DNA-dependent protein kinase | Cell death | Cell lines | Immunofluorescence | Prostate cancer | Apoptosis | Index Medicus | mTOR | melanoma | DNA-PK | non-homologous end-joining (NHEJ) | radiosensitivity
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 09/2017, Volume 82, pp. 56 - 65
Uveal melanoma | Pembrolizumab | Biomarker | Immune checkpoint blockade | Ipilimumab | Nivolumab | Life Sciences & Biomedicine | Oncology | Science & Technology | Immunotherapy - methods | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Uveal Neoplasms - secondary | Adult | Female | Retrospective Studies | C-Reactive Protein - analysis | Antibodies, Monoclonal, Humanized - therapeutic use | Biomarkers, Tumor - analysis | Proportional Hazards Models | Melanoma - secondary | Uveal Neoplasms - drug therapy | Regression Analysis | L-Lactate Dehydrogenase - blood | Melanoma - drug therapy | Survival Analysis | Aged | CTLA-4 Antigen - antagonists & inhibitors | Eosinophils - cytology | Antigens | Metastasis | Lymphocytes | Melanoma | Apoptosis | C-reactive protein | PD-1 protein | Cytotoxicity | Lymphocytes T | Malignancy | Multivariate analysis | Parameter identification | Blood | Risk factors | Skin cancer | Metastases | Proteins | CTLA-4 protein | Immunotherapy | Inhibition | Mortality | Health risks | Lactate dehydrogenase | Regression analysis | Risk analysis | Patients | Survival | L-Lactate dehydrogenase | Serum levels | Inhibitors | Immune checkpoint | Cell death | Medical prognosis | Monoclonal antibodies | Skin | Lactic acid | Index Medicus
Journal Article